News of Note—Sanofi's Dengvaxia, flu vaccines and more

non
In this week's news of note, a Philippine FDA official said Sanofi knew of Dengvaxia risks earlier than it disclosed, but a company executive denied the allegation. (Pixabay)

Here is some other vaccine news of note for the week.

> An examination of documents filed in Singapore showed that Sanofi Pasteur was aware in October 2016 that Dengvaxia shouldn’t be given to those who haven’t had dengue, according to a Philippine official. A company executive said the document outlined possible or "theoretical" risks. CNN article | Inquirer article 

> The WHO has recommended changing two flu strains currently included in flu vaccines for the next season, and an FDA advisory committee will determine whether to apply them for the U.S. WHO recommendation | FDA statement

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Supported by a £4.7 million government award, the University of Liverpool is leading a collaborative project to develop a Zika vaccine suitable for pregnant women. Release

> Emergent BioSolutions and partner Valneva have advanced their Zika vaccine candidate into human testing. Release

> South Korea’s SK Chemicals, which recently licensed its cell-based flu vaccine technology to Sanofi, plans to spin off its vaccine business into a separate subsidiary. Korea Biomedical Review article

> The Association of the British Pharmaceutical Industry said a U.K. government proposal on the methodology used to assess immunization programs would make it harder for people to access vaccines. ABPI statement